Apellis Pharmaceuticals Inc (APLS)
38.36
-3.16
(-7.61%)
USD |
NASDAQ |
Jun 28, 16:00
38.89
+0.53
(+1.38%)
After-Hours: 20:00
Apellis Pharmaceuticals Research and Development Expense (Annual): 354.39M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 354.39M |
| December 31, 2022 | 387.24M |
| December 31, 2021 | 420.87M |
| December 31, 2020 | 299.92M |
| December 31, 2019 | 220.97M |
| December 31, 2018 | 105.29M |
| Date | Value |
|---|---|
| December 31, 2017 | 40.30M |
| December 31, 2016 | 22.98M |
| December 31, 2015 | 13.73M |
| December 31, 2014 | 8.380M |
| December 31, 2013 | 2.317M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
220.97M
Minimum
2019
420.87M
Maximum
2021
336.68M
Average
354.39M
Median
2023
Research and Development Expense (Annual) Benchmarks
| Blueprint Medicines Corp | 427.72M |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Cytokinetics Inc | -- |
| Amicus Therapeutics Inc | 152.38M |
| Insmed Inc | 571.01M |